Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	aspartic-type endopeptidase activity	ERVK-6 ERVK-21 ERVK-9 ERVK-8 ERVK-24	2.00e-06	37	113	5	GO:0004190
GeneOntologyMolecularFunction	aspartic-type peptidase activity	ERVK-6 ERVK-21 ERVK-9 ERVK-8 ERVK-24	2.30e-06	38	113	5	GO:0070001
GeneOntologyMolecularFunction	(R)-limonene 6-monooxygenase activity	CYP2C19 CYP2C9	3.17e-05	2	113	2	GO:0052741
GeneOntologyMolecularFunction	(S)-limonene 6-monooxygenase activity	CYP2C19 CYP2C9	3.17e-05	2	113	2	GO:0018675
GeneOntologyMolecularFunction	(S)-limonene 7-monooxygenase activity	CYP2C19 CYP2C9	3.17e-05	2	113	2	GO:0018676
GeneOntologyMolecularFunction	limonene monooxygenase activity	CYP2C19 CYP2C9	3.17e-05	2	113	2	GO:0019113
GeneOntologyMolecularFunction	histone H3K4 methyltransferase activity	KMT2B KMT2D SETBP1	1.88e-04	20	113	3	GO:0042800
GeneOntologyMolecularFunction	arachidonate 11,12-epoxygenase activity	CYP2C19 CYP2C9	1.89e-04	4	113	2	GO:0008405
GeneOntologyMolecularFunction	linoleic acid epoxygenase activity	CYP2C19 CYP2C9	1.89e-04	4	113	2	GO:0071614
GeneOntologyMolecularFunction	RNA stem-loop binding	ERVK-6 ARID5A ERVK-8	2.18e-04	21	113	3	GO:0035613
GeneOntologyMolecularFunction	fatty acid omega-1 hydroxylase activity	CYP2C19 CYP2C9	3.14e-04	5	113	2	GO:0120502
GeneOntologyMolecularFunction	long-chain fatty acid omega-1 hydroxylase activity	CYP2C19 CYP2C9	3.14e-04	5	113	2	GO:0120319
GeneOntologyMolecularFunction	arachidonate 14,15-epoxygenase activity	CYP2C19 CYP2C9	3.14e-04	5	113	2	GO:0008404
GeneOntologyMolecularFunction	nucleoside-triphosphatase regulator activity	WAS TAGAP NUCB1 ARHGAP39 PLEKHG5 CCDC88C TBC1D10B ARHGEF40 SGSM2 ITSN2	6.12e-04	507	113	10	GO:0060589
GeneOntologyMolecularFunction	GTPase regulator activity	WAS TAGAP NUCB1 ARHGAP39 PLEKHG5 CCDC88C TBC1D10B ARHGEF40 SGSM2 ITSN2	6.12e-04	507	113	10	GO:0030695
GeneOntologyMolecularFunction	histone H3K4 monomethyltransferase activity	KMT2B KMT2D	8.69e-04	8	113	2	GO:0140945
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor	CYP2C19 CYP2C9	8.69e-04	8	113	2	GO:0033695
GeneOntologyMolecularFunction	caffeine oxidase activity	CYP2C19 CYP2C9	8.69e-04	8	113	2	GO:0034875
GeneOntologyMolecularFunction	SH3 domain binding	ESPN WAS WIPF1 SHANK3 ZNF106	1.33e-03	143	113	5	GO:0017124
GeneOntologyMolecularFunction	transcription coregulator activity	FBXL19 SRCAP PPP1R13L ARID5A KMT2D MRTFB ZBTB32 PIAS3 TLE1 TLE4	1.34e-03	562	113	10	GO:0003712
GeneOntologyMolecularFunction	histone H3K4 trimethyltransferase activity	KMT2B KMT2D	1.39e-03	10	113	2	GO:0140999
GeneOntologyMolecularFunction	unmethylated CpG binding	KMT2B FBXL19	1.39e-03	10	113	2	GO:0045322
GeneOntologyMolecularFunction	actin binding	ESPN WAS WIPF1 ESPNL RCSD1 SHANK3 MRTFB MAP1S TNS1	1.61e-03	479	113	9	GO:0003779
GeneOntologyMolecularFunction	RNA-DNA hybrid ribonuclease activity	ERVK-6 ERVK-8	1.69e-03	11	113	2	GO:0004523
GeneOntologyMolecularFunction	estrogen 16-alpha-hydroxylase activity	CYP2C19 CYP2C9	1.69e-03	11	113	2	GO:0101020
GeneOntologyMolecularFunction	G-protein alpha-subunit binding	NUCB1 CCDC88C GNAS	1.85e-03	43	113	3	GO:0001965
GeneOntologyMolecularFunction	histone H3 methyltransferase activity	KMT2B KMT2D SETBP1	1.97e-03	44	113	3	GO:0140938
GeneOntologyMolecularFunction	guanyl-nucleotide exchange factor activity	TAGAP NUCB1 PLEKHG5 CCDC88C ARHGEF40 ITSN2	2.03e-03	231	113	6	GO:0005085
GeneOntologyMolecularFunction	retinoic acid 4-hydroxylase activity	CYP2C19 CYP2C9	2.76e-03	14	113	2	GO:0008401
GeneOntologyMolecularFunction	RNA-directed DNA polymerase activity	ERVK-6 ERVK-8	2.76e-03	14	113	2	GO:0003964
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups	CYP2C19 CYP2C9	3.18e-03	15	113	2	GO:0016725
GeneOntologyMolecularFunction	ionotropic glutamate receptor binding	SHANK3 PIAS3 GNAS	3.19e-03	52	113	3	GO:0035255
GeneOntologyMolecularFunction	cytoskeletal protein binding	ESPN WAS WIPF1 KIF21A ESPNL RCSD1 KIFC2 EML3 SHANK3 CCDC88C MRTFB MAP1S GNAS TNS1	3.65e-03	1099	113	14	GO:0008092
GeneOntologyMolecularFunction	molecular adaptor activity	TANK DOK7 FBXL19 SRCAP PPP1R13L SHANK3 ARID5A KMT2D MRTFB ZBTB32 PIAS3 TLE1 TLE4 ITSN2 SHARPIN EPN1	4.01e-03	1356	113	16	GO:0060090
GeneOntologyCellularComponent	beta-catenin-TCF complex	TLE1 TLE4 TCF7L1	4.12e-05	13	112	3	GO:1990907
GeneOntologyCellularComponent	dendrite	HCN4 KIF21A CRTC1 SHANK3 GPR179 SLC6A6 NLGN3 MAP1S PIAS3 PTPRO SHARPIN IGSF9B GNAS CTNND1 BSN	5.36e-05	858	112	15	GO:0030425
GeneOntologyCellularComponent	dendritic tree	HCN4 KIF21A CRTC1 SHANK3 GPR179 SLC6A6 NLGN3 MAP1S PIAS3 PTPRO SHARPIN IGSF9B GNAS CTNND1 BSN	5.50e-05	860	112	15	GO:0097447
GeneOntologyCellularComponent	synaptic membrane	DOK7 SHANK3 GPR179 SLC6A6 NLGN3 PTPRO ITSN2 IGSF9B BSN EPN1 SEZ6L	2.98e-04	583	112	11	GO:0097060
GeneOntologyCellularComponent	postsynaptic membrane	DOK7 SHANK3 GPR179 SLC6A6 NLGN3 PTPRO IGSF9B EPN1 SEZ6L	3.34e-04	405	112	9	GO:0045211
GeneOntologyCellularComponent	postsynapse	DOK7 CRTC1 ARHGAP39 SH2D5 SHANK3 GPR179 SLC6A6 NLGN3 PIAS3 PTPRO IGSF9B CTNND1 BSN EPN1 SEZ6L	3.48e-04	1018	112	15	GO:0098794
GeneOntologyCellularComponent	inhibitory synapse	NLGN3 IGSF9B BSN	6.03e-04	31	112	3	GO:0060077
GeneOntologyCellularComponent	somatodendritic compartment	HCN4 KIF21A CRTC1 SHANK3 GPR179 SLC6A6 NLGN3 MAP1S PIAS3 PTPRO SHARPIN IGSF9B GNAS CTNND1 BSN SEZ6L	8.38e-04	1228	112	16	GO:0036477
Domain	WH2	ESPN WAS WIPF1	6.36e-05	14	107	3	SM00246
Domain	-	WAS DOK7 PLEKHG5 SH2D5 PLCD3 PHLDB1 ARHGEF40 NECAP2 ITSN2 TNS1	8.33e-05	391	107	10	2.30.29.30
Domain	Znf_PHD-finger	INTS12 KMT2B DIDO1 FBXL19 KMT2D	9.04e-05	79	107	5	IPR019787
Domain	WH2	ESPN WAS WIPF1	9.70e-05	16	107	3	PF02205
Domain	PHD	INTS12 KMT2B DIDO1 FBXL19 KMT2D	1.59e-04	89	107	5	SM00249
Domain	PH_dom-like	WAS DOK7 PLEKHG5 SH2D5 PLCD3 PHLDB1 ARHGEF40 NECAP2 ITSN2 TNS1	1.68e-04	426	107	10	IPR011993
Domain	Znf_PHD	INTS12 KMT2B DIDO1 FBXL19 KMT2D	1.77e-04	91	107	5	IPR001965
Domain	CUB	KREMEN2 CSMD3 MEGF8 SEZ6L	1.77e-04	49	107	4	PF00431
Domain	CUB	KREMEN2 CSMD3 MEGF8 SEZ6L	1.91e-04	50	107	4	SM00042
Domain	Znf_FYVE_PHD	INTS12 KMT2B DIDO1 FBXL19 KMT2D BSN	2.02e-04	147	107	6	IPR011011
Domain	ZF_PHD_2	INTS12 KMT2B DIDO1 FBXL19 KMT2D	2.16e-04	95	107	5	PS50016
Domain	-	KREMEN2 CSMD3 MEGF8 SEZ6L	2.23e-04	52	107	4	2.60.120.290
Domain	WH2_dom	ESPN WAS WIPF1	2.26e-04	21	107	3	IPR003124
Domain	ZF_PHD_1	INTS12 KMT2B DIDO1 FBXL19 KMT2D	2.27e-04	96	107	5	PS01359
Domain	CUB	KREMEN2 CSMD3 MEGF8 SEZ6L	2.40e-04	53	107	4	PS01180
Domain	CUB_dom	KREMEN2 CSMD3 MEGF8 SEZ6L	3.18e-04	57	107	4	IPR000859
Domain	FYrich_C	KMT2B KMT2D	3.22e-04	5	107	2	IPR003889
Domain	FYrich_N	KMT2B KMT2D	3.22e-04	5	107	2	IPR003888
Domain	FYRC	KMT2B KMT2D	3.22e-04	5	107	2	SM00542
Domain	FYRN	KMT2B KMT2D	3.22e-04	5	107	2	SM00541
Domain	Groucho_enhance	TLE1 TLE4	3.22e-04	5	107	2	IPR009146
Domain	TLE_N	TLE1 TLE4	3.22e-04	5	107	2	PF03920
Domain	FYRN	KMT2B KMT2D	3.22e-04	5	107	2	PF05964
Domain	FYRC	KMT2B KMT2D	3.22e-04	5	107	2	PF05965
Domain	FYRC	KMT2B KMT2D	3.22e-04	5	107	2	PS51543
Domain	FYRN	KMT2B KMT2D	3.22e-04	5	107	2	PS51542
Domain	Groucho/TLE_N	TLE1 TLE4	3.22e-04	5	107	2	IPR005617
Domain	WH2	ESPN WAS WIPF1	3.39e-04	24	107	3	PS51082
Domain	AT_hook	KMT2B SRCAP SETBP1	4.84e-04	27	107	3	SM00384
Domain	AT_hook_DNA-bd_motif	KMT2B SRCAP SETBP1	4.84e-04	27	107	3	IPR017956
Domain	Prefoldin	TANK KIF21A TLE1 TLE4	7.77e-04	72	107	4	IPR009053
Domain	TMC	TMC3 TMC8	8.90e-04	8	107	2	PF07810
Domain	TMC	TMC3 TMC8	8.90e-04	8	107	2	IPR012496
Domain	PHD	INTS12 KMT2B DIDO1 KMT2D	9.05e-04	75	107	4	PF00628
Domain	Znf_CXXC	KMT2B FBXL19	1.73e-03	11	107	2	IPR002857
Domain	ZF_CXXC	KMT2B FBXL19	1.73e-03	11	107	2	PS51058
Domain	zf-CXXC	KMT2B FBXL19	1.73e-03	11	107	2	PF02008
Domain	-	ARID5A ARID2	3.25e-03	15	107	2	1.10.150.60
Domain	BRIGHT	ARID5A ARID2	3.25e-03	15	107	2	SM00501
Domain	ARID_dom	ARID5A ARID2	3.25e-03	15	107	2	IPR001606
Domain	ARID	ARID5A ARID2	3.25e-03	15	107	2	PS51011
Domain	ARID	ARID5A ARID2	3.25e-03	15	107	2	PF01388
Domain	Post-SET_dom	KMT2B KMT2D	3.70e-03	16	107	2	IPR003616
Domain	PostSET	KMT2B KMT2D	3.70e-03	16	107	2	SM00508
Domain	POST_SET	KMT2B KMT2D	3.70e-03	16	107	2	PS50868
Domain	Homeobox_KN	MEIS3 TGIF1	4.18e-03	17	107	2	PF05920
Domain	Homeobox_KN_domain	MEIS3 TGIF1	4.18e-03	17	107	2	IPR008422
Domain	PTPc_motif	DUSP4 PTPRO TNS1	4.71e-03	59	107	3	SM00404
Domain	Tyr_Pase_cat	DUSP4 PTPRO TNS1	4.71e-03	59	107	3	IPR003595
Domain	PH	DOK7 PLEKHG5 PLCD3 PHLDB1 ARHGEF40 ITSN2	5.32e-03	278	107	6	SM00233
Domain	PH_DOMAIN	DOK7 PLEKHG5 PLCD3 PHLDB1 ARHGEF40 ITSN2	5.41e-03	279	107	6	PS50003
Domain	PH_domain	DOK7 PLEKHG5 PLCD3 PHLDB1 ARHGEF40 ITSN2	5.50e-03	280	107	6	IPR001849
Domain	Zinc_finger_PHD-type_CS	INTS12 DIDO1 FBXL19	6.17e-03	65	107	3	IPR019786
Pathway	REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX	KMT2D TLE1 TLE4 TCF7L1	1.31e-05	26	80	4	MM14793
Pathway	REACTOME_REPRESSION_OF_WNT_TARGET_GENES	TLE1 TLE4 TCF7L1	2.05e-05	10	80	3	MM15156
Pathway	REACTOME_REPRESSION_OF_WNT_TARGET_GENES	TLE1 TLE4 TCF7L1	6.12e-05	14	80	3	M27402
Pathway	REACTOME_DEACTIVATION_OF_THE_BETA_CATENIN_TRANSACTIVATING_COMPLEX	KMT2D TLE1 TLE4 TCF7L1	9.14e-05	42	80	4	M27272
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	KMT2B SZT2 FBXL19 SRCAP POM121C PLEKHG5 RASSF7 KIFC2 EML3 GGT7 PKMYT1 PLCD3 CCDC88C PHLDB1 ARHGEF40 KMT2D WIZ GAREM2 MAP1S MEGF8 CDK13 SGSM2	1.23e-11	1105	115	22	35748872
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	CDIP1 CUX2 TSPOAP1 POM121C MRTFB MAP1S PIAS3 GLI2 ARID2 SETBP1 IGSF9B BSN EPN1 NEURL4	1.81e-10	430	115	14	35044719
Pubmed	Genomewide screening for fusogenic human endogenous retrovirus envelopes identifies syncytin 2, a gene conserved on primate evolution.	ERVK-6 ERVK-21 ERVK-9 ERVK-8	5.50e-08	12	115	4	14557543
Pubmed	Protein interactome reveals converging molecular pathways among autism disorders.	TANK NUCB1 MAGI3 PPP1R13L NDUFB9 SHANK3 NLGN3 PHLDB1 PIAS3 MEGF8 SHARPIN CHRD	3.70e-07	560	115	12	21653829
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	ZNF219 HCN4 KIF21A ZBTB22 DIDO1 ARHGAP39 SHANK3 CCDC88C NLGN3 WIZ FAM171A2 CTNND1 BSN TNS1 NEURL4	7.05e-07	963	115	15	28671696
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	INTS12 MAGI3 CRTC1 PARD3B RASSF7 CCDC88C ZNF106 TBC1D10B PHLDB1 MAST4 FAM171A2 MEGF8 GNAS CTNND1	1.03e-06	861	115	14	36931259
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	ESPN MAGI3 PARD3B MEIS3 ARHGAP39 ADARB1 NLGN3 PHLDB1 MRTFB TESMIN CDK13 GLI2 SGSM2 SETBP1 AUTS2 IGSF9B GNAS CTNND1	1.94e-06	1489	115	18	28611215
Pubmed	Interaction network of human early embryonic transcription factors.	KMT2B POM121C KMT2D WIZ TLE1 ARID2 TLE4 AUTS2 INO80E	2.70e-06	351	115	9	38297188
Pubmed	Analysis of candidate genes on chromosome 2 in oral cleft case-parent trios from three populations.	COL4A3 GLI2 TNS1	2.92e-06	9	115	3	16953426
Pubmed	Functional proteomics mapping of a human signaling pathway.	KMT2B PPP1R13L PLCD3 ZNF106 KANK1 KMT2D MRTFB MAST4 PIAS3 CDK13 EPN1	4.49e-06	591	115	11	15231748
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	MAGI3 ARHGAP39 POM121C SHANK3 PLCD3 CCDC88C NLGN3 CDK13 ARID2 NEURL4	5.91e-06	493	115	10	15368895
Pubmed	All Tcf HMG box transcription factors interact with Groucho-related co-repressors.	TLE1 TLE4 TCF7L1	7.58e-06	12	115	3	11266540
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	TSPOAP1 CSMD3 PHLDB1 KANK1 MEGF8 SGSM2 TLE4 ITSN2 SEZ6L	8.89e-06	407	115	9	12693553
Pubmed	CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.	CYP2C19 CYP2C9	1.08e-05	2	115	2	16198656
Pubmed	[Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].	CYP2C19 CYP2C9	1.08e-05	2	115	2	15569425
Pubmed	Structural analyses of key features in the KANK1·KIF21A complex yield mechanistic insights into the cross-talk between microtubules and the cell cortex.	KIF21A KANK1	1.08e-05	2	115	2	29158259
Pubmed	Phosphorylation of WASp is a key regulator of activity and stability in vivo.	WAS WIPF1	1.08e-05	2	115	2	19805221
Pubmed	Two novel mutations of Wiskott-Aldrich syndrome: the molecular prediction of interaction between the mutated WASP L101P with WASP-interacting protein by molecular modeling.	WAS WIPF1	1.08e-05	2	115	2	15469902
Pubmed	Important amino acid residues that confer CYP2C19 selective activity to CYP2C9.	CYP2C19 CYP2C9	1.08e-05	2	115	2	18511451
Pubmed	Tyrosine phosphorylation of WIP releases bound WASP and impairs podosome assembly in macrophages.	WAS WIPF1	1.08e-05	2	115	2	25413351
Pubmed	Developmental expression of human hepatic CYP2C9 and CYP2C19.	CYP2C19 CYP2C9	1.08e-05	2	115	2	14634042
Pubmed	Wiskott-Aldrich syndrome protein is a key regulator of the phagocytic cup formation in macrophages.	WAS WIPF1	1.08e-05	2	115	2	17890224
Pubmed	WIP, a protein associated with wiskott-aldrich syndrome protein, induces actin polymerization and redistribution in lymphoid cells.	WAS WIPF1	1.08e-05	2	115	2	9405671
Pubmed	Disruption of PLZP in mice leads to increased T-lymphocyte proliferation, cytokine production, and altered hematopoietic stem cell homeostasis.	KMT2D ZBTB32	1.08e-05	2	115	2	15542853
Pubmed	An association between the rs1799853 and rs1057910 polymorphisms of CYP2C9, the rs4244285 polymorphism of CYP2C19 and the prevalence rates of drug-resistant epilepsy in children.	CYP2C19 CYP2C9	1.08e-05	2	115	2	32567426
Pubmed	CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract.	CYP2C19 CYP2C9	1.08e-05	2	115	2	10908295
Pubmed	Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis.	CYP2C19 CYP2C9	1.08e-05	2	115	2	17868191
Pubmed	Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.	CYP2C19 CYP2C9	1.08e-05	2	115	2	32868386
Pubmed	CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.	CYP2C19 CYP2C9	1.08e-05	2	115	2	27617498
Pubmed	Oxygenation mechanism in conversion of aldehyde to carboxylic acid catalyzed by a cytochrome P-450 isozyme.	CYP2C19 CYP2C9	1.08e-05	2	115	2	1847130
Pubmed	Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.	CYP2C19 CYP2C9	1.08e-05	2	115	2	16873909
Pubmed	Cytochromes P450 catalyze oxidation of alpha,beta-unsaturated aldehydes.	CYP2C19 CYP2C9	1.08e-05	2	115	2	17599801
Pubmed	WIP and WASP play complementary roles in T cell homing and chemotaxis to SDF-1alpha.	WAS WIPF1	1.08e-05	2	115	2	16141245
Pubmed	Comparison of the in vitro mutagenicity and metabolism of dimethylnitrosamine and benzo[a]pyrene in tissues from inbred mice treated with phenobarbital, 3-methylcholanthrene or polychlorinated biphenyls.	CYP2C19 CYP2C9	1.08e-05	2	115	2	106274
Pubmed	Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.	CYP2C19 CYP2C9	1.08e-05	2	115	2	15385837
Pubmed	[Effect of original and generic clopidogrel on prognosis in relation to different gene polymorphisms].	CYP2C19 CYP2C9	1.08e-05	2	115	2	25518510
Pubmed	Kabuki syndrome stem cell models reveal locus specificity of histone methyltransferase 2D (KMT2D/MLL4).	KMT2B KMT2D	1.08e-05	2	115	2	35640156
Pubmed	Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.	CYP2C19 CYP2C9	1.08e-05	2	115	2	15776277
Pubmed	New Structural Insights into Formation of the Key Actin Regulating WIP-WASp Complex Determined by NMR and Molecular Imaging.	WAS WIPF1	1.08e-05	2	115	2	29215267
Pubmed	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.	CYP2C19 CYP2C9	1.08e-05	2	115	2	15842554
Pubmed	Effect of cytochrome P450 2C19 and 2C9 amino acid residues 72 and 241 on metabolism of tricyclic antidepressant drugs.	CYP2C19 CYP2C9	1.08e-05	2	115	2	24492587
Pubmed	Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.	CYP2C19 CYP2C9	1.08e-05	2	115	2	19136640
Pubmed	Mouse Cyp2c expression and zonation structure in the liver begins in the early neonatal stage.	CYP2C19 CYP2C9	1.08e-05	2	115	2	35748067
Pubmed	Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.	CYP2C19 CYP2C9	1.08e-05	2	115	2	16232205
Pubmed	Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development.	CYP2C19 CYP2C9	1.08e-05	2	115	2	32587777
Pubmed	Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China.	CYP2C19 CYP2C9	1.08e-05	2	115	2	20845310
Pubmed	Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.	CYP2C19 CYP2C9	1.08e-05	2	115	2	17201743
Pubmed	Combinatorial expression patterns of individual TLE proteins during cell determination and differentiation suggest non-redundant functions for mammalian homologs of Drosophila Groucho.	TLE1 TLE4	1.08e-05	2	115	2	9572356
Pubmed	WIP regulates the stability and localization of WASP to podosomes in migrating dendritic cells.	WAS WIPF1	1.08e-05	2	115	2	17141616
Pubmed	CYP2C9 (2&3) and CYP2C19 (2&3) polymorphisms among children with nonlesional epilepsy: a single-center study.	CYP2C19 CYP2C9	1.08e-05	2	115	2	32683556
Pubmed	Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients.	CYP2C19 CYP2C9	1.08e-05	2	115	2	15855721
Pubmed	Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid.	CYP2C19 CYP2C9	1.08e-05	2	115	2	9721182
Pubmed	The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects.	CYP2C19 CYP2C9	1.08e-05	2	115	2	19847408
Pubmed	Characterization of Wiskott-Aldrich syndrome (WAS) mutants using Saccharomyces cerevisiae.	WAS WIPF1	1.08e-05	2	115	2	19817875
Pubmed	CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.	CYP2C19 CYP2C9	1.08e-05	2	115	2	17504998
Pubmed	Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors.	CYP2C19 CYP2C9	1.08e-05	2	115	2	24519941
Pubmed	Mouse liver CYP2C39 is a novel retinoic acid 4-hydroxylase. Its down-regulation offers a molecular basis for liver retinoid accumulation and fibrosis in aryl hydrocarbon receptor-null mice.	CYP2C19 CYP2C9	1.08e-05	2	115	2	14623888
Pubmed	Cytochrome P450 polymorphisms in patients with Behcet's disease.	CYP2C19 CYP2C9	1.08e-05	2	115	2	17269966
Pubmed	Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes.	CYP2C19 CYP2C9	1.08e-05	2	115	2	11950794
Pubmed	Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).	CYP2C19 CYP2C9	1.08e-05	2	115	2	17279092
Pubmed	Comparison of methylation episignatures in KMT2B- and KMT2D-related human disorders.	KMT2B KMT2D	1.08e-05	2	115	2	35506254
Pubmed	Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis.	CYP2C19 CYP2C9	1.08e-05	2	115	2	22589111
Pubmed	Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.	CYP2C19 CYP2C9	1.08e-05	2	115	2	32216088
Pubmed	cDNA cloning and sequence of CYP2C29 encoding P-450 MUT-2, a microsomal aldehyde oxygenase.	CYP2C19 CYP2C9	1.08e-05	2	115	2	8130255
Pubmed	Membrane integration of recombinant human P450 forms.	CYP2C19 CYP2C9	1.08e-05	2	115	2	19534586
Pubmed	CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.	CYP2C19 CYP2C9	1.08e-05	2	115	2	15660966
Pubmed	Targeting of δ-catenin to postsynaptic sites through interaction with the Shank3 N-terminus.	SHANK3 CTNND1	1.08e-05	2	115	2	33115499
Pubmed	Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.	CYP2C19 CYP2C9	1.08e-05	2	115	2	18154472
Pubmed	Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.	CYP2C19 CYP2C9	1.08e-05	2	115	2	27353638
Pubmed	WIP is critical for T cell responsiveness to IL-2.	WAS WIPF1	1.08e-05	2	115	2	19359486
Pubmed	WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP).	WAS WIPF1	1.08e-05	2	115	2	17213309
Pubmed	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.	CYP2C19 CYP2C9	1.08e-05	2	115	2	17298483
Pubmed	Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C93 and CYP2C193 Gene Variations With Type 2 Diabetes: A Case-Control Study.	CYP2C19 CYP2C9	1.08e-05	2	115	2	33115391
Pubmed	Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.	CYP2C19 CYP2C9	1.08e-05	2	115	2	17562299
Pubmed	Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant.	CYP2C19 CYP2C9	1.08e-05	2	115	2	36960518
Pubmed	Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.	CYP2C19 CYP2C9	1.08e-05	2	115	2	26690534
Pubmed	Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.	CYP2C19 CYP2C9	1.08e-05	2	115	2	33232775
Pubmed	Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.	CYP2C19 CYP2C9	1.08e-05	2	115	2	19199010
Pubmed	Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.	CYP2C19 CYP2C9	1.08e-05	2	115	2	17304159
Pubmed	Genetic Polymorphisms of CYP2C9/CYP2C19 in Chronic Obstructive Pulmonary Disease.	CYP2C19 CYP2C9	1.08e-05	2	115	2	32757668
Pubmed	A comparative analysis of binding sites between mouse CYP2C38 and CYP2C39 based on homology modeling, molecular dynamics simulation and docking studies.	CYP2C19 CYP2C9	1.08e-05	2	115	2	19358898
Pubmed	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.	CYP2C19 CYP2C9	1.08e-05	2	115	2	20390258
Pubmed	Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians.	CYP2C19 CYP2C9	1.08e-05	2	115	2	19761366
Pubmed	Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.	CYP2C19 CYP2C9	1.08e-05	2	115	2	14616425
Pubmed	Cyp2c-deficiency depletes muricholic acids and protects against high-fat diet-induced obesity in male mice but promotes liver damage.	CYP2C19 CYP2C9	1.08e-05	2	115	2	34438105
Pubmed	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.	CYP2C19 CYP2C9	1.08e-05	2	115	2	12496751
Pubmed	Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.	CYP2C19 CYP2C9	1.08e-05	2	115	2	24403552
Pubmed	Chromosomal organization of the cytochrome P450-2C gene family in the mouse: a locus associated with constitutive aryl hydrocarbon hydroxylase.	CYP2C19 CYP2C9	1.08e-05	2	115	2	2895926
Pubmed	X-linked thrombocytopenia caused by a mutation in the Wiskott-Aldrich syndrome (WAS) gene that disrupts interaction with the WAS protein (WASP)-interacting protein (WIP).	WAS WIPF1	1.08e-05	2	115	2	12591280
Pubmed	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers.	CYP2C19 CYP2C9	1.08e-05	2	115	2	20831536
Pubmed	WASP suppresses the growth defect of Saccharomyces cerevisiae las17Delta strain in the presence of WIP.	WAS WIPF1	1.08e-05	2	115	2	16488394
Pubmed	The Epigenetic Factor Landscape of Developing Neocortex Is Regulated by Transcription Factors Pax6→ Tbr2→ Tbr1.	KMT2B SRCAP KMT2D ARID2 AUTS2 INO80E	1.44e-05	157	115	6	30186101
Pubmed	A revised nomenclature for transcribed human endogenous retroviral loci.	ERVK-6 ERVK-21 ERVK-9 ERVK-8 ERVK-24	1.57e-05	94	115	5	21542922
Pubmed	Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst.	CUX2 ZNF219 INTS12 ZBTB22 DIDO1 FBXL19 SRCAP TGIF1 WIZ PIAS3 ARID2 TCF7L1	1.58e-05	808	115	12	20412781
Pubmed	Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.	KMT2B DIDO1 SRCAP MAST4 CTNND1	2.57e-05	104	115	5	9205841
Pubmed	Prediction of the coding sequences of unidentified human genes. VIII. 78 new cDNA clones from brain which code for large proteins in vitro.	SGSM2 SETBP1 AUTS2 BSN	2.72e-05	52	115	4	9455477
Pubmed	Expression patterns of transcribed human endogenous retrovirus HERV-K(HML-2) loci in human tissues and the need for a HERV Transcriptome Project.	ERVK-21 ERVK-9 ERVK-24	2.77e-05	18	115	3	18664271
Pubmed	Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.	CYP2C19 CYP2C9	3.24e-05	3	115	2	28687336
Pubmed	CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.	CYP2C19 CYP2C9	3.24e-05	3	115	2	16220110
Pubmed	Cytochrome p450 genotyping by multiplexed real-time dna sequencing with pyrosequencing technology.	CYP2C19 CYP2C9	3.24e-05	3	115	2	15090156
Interaction	TOP3B interactions	KMT2B SZT2 FBXL19 SRCAP POM121C PLEKHG5 RASSF7 KIFC2 EML3 GGT7 PKMYT1 PLCD3 CCDC88C PHLDB1 ARHGEF40 KMT2D WIZ GAREM2 MAP1S MEGF8 CDK13 SGSM2 GNAS	3.62e-06	1470	110	23	int:TOP3B
Cytoband	8q24.3	COL22A1 ARHGAP39 KIFC2 SHARPIN	1.95e-04	113	115	4	8q24.3
Cytoband	1p36.31	ESPN PLEKHG5	5.55e-04	14	115	2	1p36.31
GeneFamily	PHD finger proteins	INTS12 KMT2B DIDO1 FBXL19 KMT2D	4.07e-05	90	77	5	88
GeneFamily	TALE class homeoboxes and pseudogenes	MEIS3 TGIF1 MEIS3P2	1.80e-04	26	77	3	526
GeneFamily	Transmembrane channel likes	TMC3 TMC8	4.93e-04	8	77	2	1135
GeneFamily	Zinc fingers CXXC-type	KMT2B FBXL19	1.15e-03	12	77	2	136
GeneFamily	AT-rich interaction domain containing	ARID5A ARID2	1.81e-03	15	77	2	418
GeneFamily	Ankyrin repeat domain containing	ESPN ESPNL PPP1R13L SHANK3 KANK1	3.72e-03	242	77	5	403
GeneFamily	PDZ domain containing	MAGI3 PARD3B SHANK3 MAST4	4.04e-03	152	77	4	1220
GeneFamily	Fibronectin type III domain containing	TSPOAP1 CSF2RB PTPRO IGSF9B	4.84e-03	160	77	4	555
Coexpression	MANALO_HYPOXIA_UP	PPP1R13L MAST4 TLE1 ALPK3 TNS1 MN1 TCF7L1	2.60e-05	205	110	7	M259
Coexpression	NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_DN	COL4A3 CYP2C9 HCN4 SRCAP ADARB1 PHLDB1 ZBTB32 MAST4 WIZ MEGF8 TLE4 EPN1 TNS1 SEZ6L	2.76e-05	909	110	14	M41018
Coexpression	LIM_MAMMARY_STEM_CELL_UP	ZNF219 WIPF1 SCARF2 RCSD1 ADARB1 SLC4A3 SH2D5 PHLDB1 TNS1 TCF7L1	3.47e-05	479	110	10	M2573
Coexpression	LIM_MAMMARY_STEM_CELL_UP	ZNF219 WIPF1 SCARF2 RCSD1 ADARB1 SLC4A3 SH2D5 PHLDB1 TNS1 TCF7L1	3.73e-05	483	110	10	MM1082
Coexpression	VARELA_ZMPSTE24_TARGETS_UP	CUX2 CYP2C19 CYP2C9 ADARB1	3.83e-05	45	110	4	MM1200
CoexpressionAtlas	MESO-30 amniotic fluid MSC_vs_MESO-30 blastocyst-Confounder_removed-fold2.0_adjp0.05	ESPN CUX2 ZNF219 TSPOAP1 MAGI3 CRTC1 PARD3B COL22A1 POM121C ADARB1 PLEKHG5 SLC4A3 SHANK3 CCDC88C FAM171A2 GLI2 ARID2 TLE4 MN1 TCF7L1	4.14e-06	1245	108	20	PCBC_ratio_MESO-30 amniotic fluid MSC_vs_MESO-30 blastocyst_cfr-2X-p05
ToppCell	PBMC-Severe-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-6\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	COL4A3 KREMEN2 DOK7 ZBTB32 SMIM14 TLE1 SETBP1 CCDC24	2.91e-08	194	110	8	2b5eee7c3e52b63cce94205d18133c7704329c02
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27\|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)	COL4A3 RCSD1 TGIF1 MRTFB TLE1 SETBP1 ITSN2	3.16e-07	179	110	7	a28a1de500a74c6dcc43481abf9ec0f7e7a300a9
ToppCell	normal-na-Lymphocytic_B-B_mem-male\|normal / PBMC cell types (v2) per disease, treatment status, and sex	COL4A3 RCSD1 TMC3 ZBTB32 TLE1 SETBP1 ITSN2	3.54e-07	182	110	7	ee36ea6cb9a5a08aeb83f2b7a249255f0b1a9870
ToppCell	critical-Lymphoid-B_cell\|critical / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	COL4A3 DOK7 RCSD1 ZBTB32 SMIM14 SETBP1 TMC8	4.90e-07	191	110	7	0716cfaeb11d9c90c18fa8f9d50c9c6fb5182848
ToppCell	Adult-Epithelial\|Adult / Lineage, Cell type, age group and donor	COL4A3 MAGI3 PARD3B KANK1 MAST4 AUTS2 TCF7L1	5.07e-07	192	110	7	efb962a5fd3b9bdfd8cf8d13c435e29c8271713e
ToppCell	BAL-Control-Lymphocyte-B-B_cell-B_cell-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	COL4A3 KREMEN2 DOK7 DUSP4 RCSD1 ZBTB32 SETBP1	5.25e-07	193	110	7	bcda1fb3db7d4c276e3370250a2b79fedd807fc5
ToppCell	COVID-19_Severe-Lymphoid_B-B_intermediate\|COVID-19_Severe / Disease group, lineage and cell class	COL4A3 DOK7 ZBTB32 SMIM14 TLE1 SETBP1 CCDC24	5.25e-07	193	110	7	ea079e6f7242a2bbc8260299ad9e9bdabb9856f8
ToppCell	BAL-Control-Lymphocyte-B-B_cell-B_cell\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	COL4A3 KREMEN2 DOK7 DUSP4 RCSD1 ZBTB32 SETBP1	5.25e-07	193	110	7	befab58da635723db4f9270d087afa981fc45bf1
ToppCell	Control-B_cell-B_cell\|Control / Disease group,lineage and cell class （2021.01.30）	COL4A3 KREMEN2 DOK7 DUSP4 RCSD1 ZBTB32 SETBP1	5.25e-07	193	110	7	d43099c0b8ca68048d6497c4db89d6d5155375f9
ToppCell	BAL-Control-Lymphocyte-B-B_cell\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	COL4A3 KREMEN2 DOK7 DUSP4 RCSD1 ZBTB32 SETBP1	5.25e-07	193	110	7	ba826e6e035e48e1b497af1081c43339b0019e76
ToppCell	PBMC-Severe-Lymphocyte-B-B_cell-B_intermediate\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	COL4A3 DOK7 ZBTB32 SMIM14 TLE1 SETBP1 CCDC24	5.44e-07	194	110	7	7f62bd52779e2779447b23bdd330be4b5b35910a
ToppCell	Control-B_cell\|Control / Disease group,lineage and cell class （2021.01.30）	COL4A3 KREMEN2 DOK7 DUSP4 RCSD1 ZBTB32 SETBP1	5.44e-07	194	110	7	8388fe4df3461d85b21bd6847a4d32c030aaece4
ToppCell	BAL-Control-Lymphocyte-B\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	COL4A3 KREMEN2 DOK7 DUSP4 RCSD1 ZBTB32 SETBP1	5.44e-07	194	110	7	1537e2285d0a8d0a4175dd0b8b1d1ccd887229fc
ToppCell	severe-B_intermediate\|severe / disease stage, cell group and cell class	COL4A3 KREMEN2 ZBTB32 SMIM14 TLE1 SETBP1 CCDC24	5.83e-07	196	110	7	8f59e51ca50bef4753f67cd1efdb02665805a120
ToppCell	severe_COVID-19-B_intermediate\|severe_COVID-19 / disease group, cell group and cell class (v2)	COL4A3 TAGAP DOK7 ZBTB32 SMIM14 TLE1 SETBP1	6.03e-07	197	110	7	3ba64850b344cb24a4d20d64392a0b2752950d40
ToppCell	COVID-19-COVID-19_Severe-Lymphocyte-B-B_intermediate\|COVID-19_Severe / Disease, condition lineage and cell class	COL4A3 DOK7 ZBTB32 SMIM14 TLE1 SETBP1 CCDC24	6.45e-07	199	110	7	ad3c369a67926725917b771094f82ca6dd2af783
ToppCell	COVID-CD4-CD4_Treg\|COVID / Condition, Cell_class and T cell subcluster	TAGAP TSPOAP1 GGT7 KMT2D MAST4 TMC8	2.80e-06	159	110	6	037cd97c41eb2f91fd3f69bbb3ffdfd6c0158410
ToppCell	IIH-naiveBc\|IIH / Condition, Cell_class and T cell subcluster	COL4A3 KREMEN2 DOK7 ZBTB32 SMIM14 SETBP1	3.85e-06	168	110	6	8450ed6720d308c711dfbc76652e5821be7b8e93
ToppCell	IIH-naiveBc-\|IIH / Condition, Cell_class and T cell subcluster	COL4A3 KREMEN2 DOK7 ZBTB32 SMIM14 SETBP1	3.85e-06	168	110	6	27b500f79aedc4669988670c92ff1a47dcbdf2a0
ToppCell	3'_v3-Lung-Lymphocytic_B-Memory_B_cells\|Lung / Manually curated celltypes from each tissue	COL4A3 ESPNL TMC3 ZBTB32 TLE1 SETBP1	4.26e-06	171	110	6	9ecef653f6916572bf5fbee5aea6c577d04e96ba
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell-B_c04-SOX5-TNFRSF1B\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	COL4A3 KMT2B ZBTB32 SMIM14 SETBP1 ITSN2	4.71e-06	174	110	6	ebe6ce173ad12d4a2afa39f8d6185c0e4f97fb1e
ToppCell	PBMC-Severe-Lymphocyte-B-B_cell-B_memory-B_memory-6\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	DOK7 ZBTB32 SMIM14 TLE1 SETBP1 CCDC24	4.87e-06	175	110	6	eaec7fda07a9537d067ca13b607a8ab201caa7c4
ToppCell	facs-Brain_Non-Myeloid-Hippocampus-3m-Epithelial-neuronal_stem_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NLGN3 KANK1 GAREM2 PTPRO IGSF9B SEZ6L	5.91e-06	181	110	6	4e81ec1580e9acb22c32c465eb46f83d1e9e424e
ToppCell	facs-Brain_Non-Myeloid-Hippocampus-3m-Epithelial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NLGN3 KANK1 GAREM2 PTPRO IGSF9B SEZ6L	5.91e-06	181	110	6	ad30c01290fb98adbd0caed301a584761212c977
ToppCell	facs-Brain_Non-Myeloid-Hippocampus-3m-Epithelial-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NLGN3 KANK1 GAREM2 PTPRO IGSF9B SEZ6L	5.91e-06	181	110	6	3a3268a4dff8ffcb79e09f46490e138c96f8d916
ToppCell	15-Trachea-Immune-Hematopoietic,_B_Cells\|Trachea / Age, Tissue, Lineage and Cell class	CUX2 WAS WIPF1 RCSD1 CSF2RB PTPRO	6.10e-06	182	110	6	1424d990598d37b22fa44df032be97c1cd1363d1
ToppCell	Severe_COVID-19-B_cell-B_cell\|Severe_COVID-19 / Disease group,lineage and cell class （2021.01.30）	COL4A3 RCSD1 ZBTB32 SMIM14 TLE1 SETBP1	6.29e-06	183	110	6	5634e528001c389efd1e380f01ad40072f60e943
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	COL4A3 INTS12 PARD3B KANK1 PTPRO TCF7L1	6.29e-06	183	110	6	3c516fe5083f02bad1f464ed284010b4131a833c
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	COL4A3 INTS12 PARD3B KANK1 PTPRO TCF7L1	6.29e-06	183	110	6	9c2689d76fc6d30f5ab093428aa669d0a98953cf
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Renal_corpuscle_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	COL4A3 INTS12 PARD3B KANK1 PTPRO TCF7L1	6.49e-06	184	110	6	7294b379ce4cb8fa75e432559082f93cd106aaf5
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL4A3 MAGI3 PPP1R13L RASSF7 KIFC2 SLC6A6	6.90e-06	186	110	6	3aebe163799109ffc67e4e10ee47c2dd0886a92c
ToppCell	droplet-Lung-21m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l27\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	FBXL19 PPP1R13L PLCD3 KANK1 SETBP1 TCF7L1	6.90e-06	186	110	6	c116cc9f41971622264434ebe29d18e719b0ae19
ToppCell	Healthy_donor-B_memory\|Healthy_donor / disease group, cell group and cell class (v2)	COL4A3 TAGAP DOK7 ZBTB32 TLE1 TCF7L1	7.80e-06	190	110	6	46104a521f00d399315deca86699cb261b2795d6
ToppCell	3'_v3-Lung-Lymphocytic_T_CD8-Trm/em_CD8\|Lung / Manually curated celltypes from each tissue	TAGAP KIF21A DUSP4 ADARB1 CCDC88C AUTS2	7.80e-06	190	110	6	74638e470ece8016465bbebc1756ffa6d605b25f
ToppCell	severe_COVID-19-B_memory\|World / disease group, cell group and cell class (v2)	COL4A3 TAGAP DOK7 ESPNL ZBTB32 TLE1	8.03e-06	191	110	6	3b57e353b74ebc866d0e11deeba31fa764c42325
ToppCell	10x5'v1-week_17-19-Endothelial-stroma-proliferating_EC\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	DUSP4 SHANK3 ALPK3 CHRD BSN TCF7L1	8.03e-06	191	110	6	dc9e5eb6aa31b8d79aeec33e59b9138dfb469a3b
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_B-B_cell-B_c02-MS4A1-CD27\|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)	TANK TAGAP CSF2RB TLE1 SETBP1 ITSN2	8.53e-06	193	110	6	08696a99309f5b088692ddac8cca35413b5e810d
ToppCell	PBMC-Severe-Lymphocyte-B-B_cell-B_intermediate-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	COL4A3 ZBTB32 SMIM14 TLE1 SETBP1 CCDC24	8.53e-06	193	110	6	b5e44fe60dc84dc050d4fa3ccec4e257e51dc636
ToppCell	PBMC-Severe-Lymphocyte-B-B_cell-B_intermediate\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	COL4A3 ZBTB32 SMIM14 TLE1 SETBP1 CCDC24	8.53e-06	193	110	6	e2cf2f4f142e1b4dda3ded28b5208eef3f301a43
ToppCell	human_hepatoblastoma-Tumor_cells\|human_hepatoblastoma / Sample and Cell Type and Tumor Cluster (all cells)	CUX2 KIF21A MAGI3 DIDO1 PARD3B KANK1	8.53e-06	193	110	6	503a979328c68b096680b71359a26f02fafdff35
ToppCell	MS-naiveBc\|MS / Condition, Cell_class and T cell subcluster	COL4A3 KREMEN2 DOK7 ZBTB32 SMIM14 SETBP1	8.78e-06	194	110	6	aa4aa0a61275610054b583f60d5d41ecc4f88a0d
ToppCell	severe_COVID-19-B_intermediate\|World / disease group, cell group and cell class (v2)	COL4A3 DOK7 ZBTB32 SMIM14 TLE1 SETBP1	8.78e-06	194	110	6	cb346cb186fe80a8f490ae90b2539b3543ba0ca9
ToppCell	Control-Lymphoid-Plasma,_B_cells\|Control / Condition, Lineage and Cell class	COL4A3 KREMEN2 DUSP4 RCSD1 ZBTB32 SETBP1	8.78e-06	194	110	6	31fff4361ebed6308b1e6b2b705ee6e0a695bd0c
ToppCell	systemic_lupus_erythematosus-managed-Lymphocytic_B-B_mem\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	COL4A3 DOK7 ZBTB32 SMIM14 TLE1 SETBP1	8.78e-06	194	110	6	9657aef9f11d02d2f0e5cd4b4d8ba23eb2750d92
ToppCell	nucseq-Epithelial-Epithelial_Alveolar\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL4A3 MAGI3 PARD3B KANK1 MAST4 CTNND1	8.78e-06	194	110	6	53f3e49e91b1096f3226010e2de767efb490dfe4
ToppCell	MS-naiveBc-\|MS / Condition, Cell_class and T cell subcluster	COL4A3 KREMEN2 DOK7 ZBTB32 SMIM14 SETBP1	8.78e-06	194	110	6	1757787246a7862f9709834efc62bac61d70b906
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell-D032\|Children_(3_yrs) / Lineage, Cell type, age group and donor	MEIS3 PHLDB1 GLI2 SETBP1 CHRD MN1	9.04e-06	195	110	6	ff0aa455e9844a6d7ae57ff59fb6cea825cf1fc2
ToppCell	severe-B_intermediate\|World / disease stage, cell group and cell class	COL4A3 KREMEN2 ZBTB32 SMIM14 TLE1 CCDC24	9.04e-06	195	110	6	ce4bd004ceb05a269387adfed255d7fa393afcc6
ToppCell	systemic_lupus_erythematosus-managed-Lymphocytic_B-B_mem-female\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	COL4A3 DOK7 ZBTB32 SMIM14 TLE1 SETBP1	9.04e-06	195	110	6	a4a3dc54b88bcdd82966ee0d5f7be00f227f5457
ToppCell	nucseq-Epithelial\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL4A3 MAGI3 PARD3B KANK1 MAST4 CTNND1	9.04e-06	195	110	6	9406866f99555198a9be311fbd65751b70f35446
ToppCell	facs-Skin-Telogen-3m-Epithelial-bulge_keratinocyte\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ARID5A SLC6A6 KANK1 SETBP1 TNS1 MN1	9.31e-06	196	110	6	90edf61116ffcb4f8b6be3d0a05732d59b0a87d5
ToppCell	severe_COVID-19-B_memory\|severe_COVID-19 / disease group, cell group and cell class (v2)	COL4A3 TAGAP DOK7 ZBTB32 TLE1 SETBP1	9.31e-06	196	110	6	c6e00cb59a88b9903cca233cefe05f80c5ea4153
ToppCell	mild_COVID-19-B_intermediate\|mild_COVID-19 / disease group, cell group and cell class (v2)	COL4A3 TAGAP ZBTB32 SMIM14 TLE1 SETBP1	9.58e-06	197	110	6	f669500120646f69355a6f920b892a6f2faeab63
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-B_lymphocytic-memory_B_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	COL4A3 DOK7 RCSD1 SMIM14 TLE1 SETBP1	9.58e-06	197	110	6	43e576bd6997915d21137e233e36984eba31f637
ToppCell	MS-IIF-Lymphocyte-B-B_intermediate\|IIF / Disease, condition lineage and cell class	COL4A3 RCSD1 ZBTB32 SMIM14 TLE1 SETBP1	9.86e-06	198	110	6	d6b533c5e1d55e13b1e87ce3dbacb1564bcdcc64
ToppCell	severe-B_intermediate\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	COL4A3 ZBTB32 SMIM14 TLE1 SETBP1 CCDC24	1.01e-05	199	110	6	17283d75a2a900369f63ed02996e7ede97f46140
ToppCell	5'-Adult-LymphNode\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	WAS WIPF1 TAGAP RCSD1 ARID5A TMC8	1.01e-05	199	110	6	098ff8badf67c382d8ddfa6b33f5035a26f2fd5f
ToppCell	severe-B_intermediate\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	COL4A3 ZBTB32 SMIM14 TLE1 SETBP1 CCDC24	1.04e-05	200	110	6	6d0ac3d00400dd5657ee266f7b885381bf790ce1
ToppCell	5'-Adult-LymphNode-Hematopoietic\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	WAS WIPF1 TAGAP RCSD1 ARID5A TMC8	1.04e-05	200	110	6	7dee3da190c78cb72970123eb8768618584ebeea
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Slc17a6-Excitatory_Neuron.Slc17a6.Oprk1_(Claustrum_cortex)\|Striatum / BrainAtlas - Mouse McCarroll V32	DOK7 DUSP4 COL22A1 PLCD3 IGSF9B	1.66e-05	128	110	5	7e3f5cea91af005f08d8e9340fb8630bf1c887c3
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Slc17a6\|Striatum / BrainAtlas - Mouse McCarroll V32	DOK7 DUSP4 COL22A1 PLCD3 IGSF9B	1.66e-05	128	110	5	a876303c852db2af9418d1a1711d7c950805018a
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Slc17a6-Excitatory_Neuron.Slc17a6.Oprk1_(Claustrum_cortex)-\|Striatum / BrainAtlas - Mouse McCarroll V32	DOK7 DUSP4 COL22A1 PLCD3 IGSF9B	1.66e-05	128	110	5	388062f840fd04cb8087f27a9a78e7a192920e3e
ToppCell	facs-Pancreas-Exocrine-3m-Hematologic-leukocyte\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	WAS TAGAP RCSD1 CSF2RB PTPRO	3.34e-05	148	110	5	bbf4933582b50b3412c805de5ed137107c996236
ToppCell	facs-Pancreas-Exocrine-3m-Hematologic-nan\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	WAS TAGAP RCSD1 CSF2RB PTPRO	3.34e-05	148	110	5	6543860e3207a7de92a35bb6004be51287582f7a
ToppCell	facs-Pancreas-Exocrine-3m-Hematologic\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	WAS TAGAP RCSD1 CSF2RB PTPRO	3.34e-05	148	110	5	79e376503a3f9504a1ec5af4a60a09cc80e19059
ToppCell	10x5'-Lung-Lymphocytic_B-ABC_aged-B_memory\|Lung / Manually curated celltypes from each tissue	COL4A3 DOK7 GJA3 ZBTB32 SETBP1	4.70e-05	159	110	5	d3202ddc291b8686dbe67690df13c7daffec2199
ToppCell	droplet-Marrow-BM-30m-Myeloid-basophil\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KIFC2 ARHGEF40 TESMIN CTNND1 NEURL4	5.13e-05	162	110	5	75df7ff779a3b9159ba97d852da1f8df650b9ce5
ToppCell	TCGA-Mesothelium-Primary_Tumor-Mesothelioma-Biphasic\|TCGA-Mesothelium / Sample_Type by Project: Shred V9	SCARF2 PKMYT1 ARHGEF40 PIAS3 TCF7L1	5.93e-05	167	110	5	9062577a4b7902c9a888d706589d1b05221c0fa8
ToppCell	CV-Mild-6\|CV / Virus stimulation, Condition and Cluster	MAGI3 NLGN3 KANK1 TMC8 CTNND1	5.93e-05	167	110	5	cf2ed0b6d17a16f9a2318879ce8856d5983ad3cf
ToppCell	3'_v3-GI_small-bowel-Lymphocytic_B-Memory_B_cells\|GI_small-bowel / Manually curated celltypes from each tissue	COL4A3 ESPNL SMIM14 TLE1 SETBP1	6.10e-05	168	110	5	8e025bb0541746e232b77ac0e31412ae71420c47
ToppCell	3'_v3-GI_small-bowel-Lymphocytic_B\|GI_small-bowel / Manually curated celltypes from each tissue	COL4A3 ESPNL SMIM14 TLE1 SETBP1	6.10e-05	168	110	5	5535c1b8b7fde7b59a1bc0580cebdfa963aa1c39
ToppCell	367C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_0\|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells)	TSPOAP1 SRCAP MAP1S MEGF8 TNS1	6.10e-05	168	110	5	2fb2d916eb5000a637240d38e47a9b4f61f9f83f
ToppCell	3'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells-Mast_cells_L.1.4.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	KREMEN2 PARD3B ZBTB32 TESMIN TMC8	6.10e-05	168	110	5	55f328353119cbdc521c782ebb8d163876f4186d
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	COL4A3 GJA3 NLGN3 PTPRO TCF7L1	6.45e-05	170	110	5	60bbd738c12e64e483485586c30057304884f5a6
ToppCell	facs-Lung-18m-Hematologic-lymphocytic-CD4-positive,_alpha-beta_T_cell-CD4-positive,_alpha-beta_T_cell_l21\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ESPN TAGAP DUSP4 ZBTB32 NEURL4	6.45e-05	170	110	5	bda900c836e0f2c1d7b442beb50b672d025b2420
ToppCell	droplet-Lung-1m-Hematologic-lymphocytic-CD4-positive,_alpha-beta_T_cell-CD4-positive,_alpha-beta_T_cell_l21\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TAGAP KREMEN2 RASSF7 NLGN3 ZBTB32	6.82e-05	172	110	5	30f4979abf0218618a56afb06aa6afc23ad838ec
ToppCell	Mild/Remission-B_naive-8\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	TAGAP RCSD1 ADARB1 SMIM14 TLE1	7.01e-05	173	110	5	694d02c4d2dc2de4b344544f9124fec40fcf7d8f
ToppCell	mild_COVID-19_(asymptomatic)-B_memory\|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2)	COL4A3 TAGAP DOK7 ZBTB32 TCF7L1	7.01e-05	173	110	5	9082ad77b44f65b72094df6e502cce81b62fe81a
ToppCell	facs-Pancreas-Exocrine-3m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HCN4 MAST4 IGSF9B BSN SEZ6L	7.20e-05	174	110	5	f1fe1f4216748a9562dd03bd48c70b23c7ff4d1d
ToppCell	droplet-Heart-HEART_(ALL_4:4:4:1:1)-30m-Hematologic-nan\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	WAS KREMEN2 RASSF7 PKMYT1 ZBTB32	7.40e-05	175	110	5	3bca1aac2a2a1f46753b5f9462888f144ed8327b
ToppCell	PBMC-Mild-Lymphocyte-B-B_cell-B_memory-B_memory-6\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	KREMEN2 DOK7 ZBTB32 SMIM14 TLE1	7.40e-05	175	110	5	1b3510e9078eec7cfc5805043e435e9e5e0f0877
ToppCell	CV-Mild-6\|Mild / Virus stimulation, Condition and Cluster	MAGI3 ZNF106 NLGN3 KANK1 CTNND1	7.40e-05	175	110	5	c4d530dbb37942427c9cd0a1533faeb6a3a45381
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	COL4A3 INTS12 PARD3B PTPRO TCF7L1	7.81e-05	177	110	5	4d2cdb57b427a42085c5f9affa0967b15e84dec3
ToppCell	PBMC-Convalescent-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-0\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	COL4A3 ZBTB32 SMIM14 TLE1 CCDC24	8.02e-05	178	110	5	be1d991c5a0a5be22f14f57d34ee1330f1a12963
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	COL4A3 INTS12 PARD3B PTPRO TCF7L1	8.02e-05	178	110	5	edc7143dc9959d36057cb9471681a23afcbc8cce
ToppCell	CTRL-Lymphoid-B_cell\|CTRL / Disease state, Lineage and Cell class	COL4A3 RCSD1 CCDC88C ZBTB32 SETBP1	8.23e-05	179	110	5	dd4055c0a8360ea10323ef6249519a6ae08fc05a
ToppCell	Control-Epithelial_cells-AT2\|Control / group, cell type (main and fine annotations)	MAGI3 KANK1 MAST4 AUTS2 TCF7L1	8.45e-05	180	110	5	198b19e7910b4a8cc7e820c525ab357c7f99f578
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL4A3 MAGI3 PPP1R13L RASSF7 KIFC2	8.67e-05	181	110	5	b45b11428d13950369347e051d4d517efb2bd4fd
ToppCell	normal_Lymph_Node-T/NK_cells-Exhausted_CD8+_T\|T/NK_cells / Location, Cell class and cell subclass	WIPF1 KIF21A DUSP4 ZBTB32 TNS1	8.67e-05	181	110	5	7e12030965881b023f0d3d27d934fa648e2cc523
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_B-B_cell-B_c04-SOX5-TNFRSF1B\|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)	ZBTB32 SMIM14 TLE1 SETBP1 ITSN2	8.67e-05	181	110	5	0bc58c8942491e7ee5b858c5742770df7677532f
ToppCell	PBMC-Control-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-6\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	COL4A3 KREMEN2 ZBTB32 SMIM14 SETBP1	9.13e-05	183	110	5	82fe14fc7039415de41bdfd615a1380bed99f560
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Renal_corpuscle_epithelial_cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	COL4A3 INTS12 PARD3B PTPRO TCF7L1	9.13e-05	183	110	5	848fc6dd129150897ee339343e83c645b6e779eb
ToppCell	Control-Endothelial-Endothelial-Activated_Alv_Cap\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	RCSD1 SHANK3 MRTFB NECAP2 TLE4	9.13e-05	183	110	5	e81c142770f44fd902b0631bc360c5b5339d4c75
ToppCell	LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	COL4A3 KIF21A MAGI3 RASSF7 KIFC2	9.37e-05	184	110	5	42ce855b4f8475a8298192feec785bdc69bc5bb0
ToppCell	3'-Child09-12-SmallIntestine-Hematopoietic-B_cells-FCRL4+_Memory_B\|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	KREMEN2 RCSD1 ZBTB32 SMIM14 SETBP1	9.37e-05	184	110	5	95cf125127658c4c04445c61809d1aed21ee1f83
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL4A3 MAGI3 PARD3B CTNND1 TNS1	9.37e-05	184	110	5	57c792e6e2fedba25d3350ffe649fd74750b579d
ToppCell	3'-Adult-LargeIntestine-Hematopoietic-T_cells-ILC3\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	WAS WIPF1 TAGAP RCSD1 TLE1	9.37e-05	184	110	5	2f9c5887635185dc1c6ec4e959b6d8a28b0bd020
ToppCell	Healthy/Control-B_memory\|World / Disease group and Cell class	COL4A3 KREMEN2 DOK7 ZBTB32 TLE1	9.37e-05	184	110	5	9e1879d86b535ede9b47deb0752e291f987a5d5e
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	COL4A3 MAGI3 PARD3B CTNND1 TNS1	9.37e-05	184	110	5	d7bd0f0c607bade67c99e9fb3578a570298bf926
ToppCell	PBMC-Convalescent-Lymphocyte-B-B_cell-B_memory-B_memory-3\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	COL4A3 KREMEN2 DOK7 SMIM14 TLE1	9.61e-05	185	110	5	05e6eb78ead81268c1656e7ffe34f9cb7329b908
Drug	Tenoxicam [59804-37-4]; Up 200; 11.8uM; MCF7; HT_HG-U133A	COL4A3 WAS WIPF1 SZT2 SRCAP TESMIN FUT4 TNS1 TCF7L1	4.02e-07	194	109	9	4182_UP
Drug	Retrorsine [480-54-6]; Down 200; 11.4uM; HL60; HT_HG-U133A	ZNF219 SZT2 NUCB1 SRCAP PTPRO SGSM2 SHARPIN TNS1	4.22e-06	193	109	8	2129_DN
Drug	estradiol, USP; Down 200; 0.01uM; HL60; HT_HG-U133A	COL4A3 CUX2 WAS HCN4 TSPOAP1 DUSP4 SRCAP SGSM2	4.55e-06	195	109	8	6200_DN
Drug	Levodopa [59-92-7]; Up 200; 20.2uM; MCF7; HT_HG-U133A	WAS WIPF1 HCN4 TSPOAP1 KREMEN2 SLC6A6 CDK13 TNS1	4.91e-06	197	109	8	4394_UP
Drug	Pepstatin A [26305-03-3]; Down 200; 5.8uM; MCF7; HT_HG-U133A	WAS WIPF1 CRTC1 ADARB1 PHLDB1 MAST4 AUTS2 FUT4	5.09e-06	198	109	8	3264_DN
Drug	Perhexiline maleate [6724-53-4]; Up 200; 10.2uM; MCF7; HT_HG-U133A	ZNF219 DUSP4 CRTC1 TGIF1 PTPRO TLE4 AUTS2	1.80e-05	170	109	7	5501_UP
Drug	dibenzylfluorescein	CYP2C19 CYP2C9	2.27e-05	2	109	2	ctd:C558664
Drug	Megestrol acetate [595-33-5]; Up 200; 10.4uM; MCF7; HT_HG-U133A	SRCAP SLC6A6 MAST4 WIZ CDK13 TLE4 FUT4	3.92e-05	192	109	7	5013_UP
Drug	vinblastine sulfate; Up 200; 0.1uM; PC3; HT_HG-U133A	HNF1B SRCAP ADARB1 EML3 CCDC88C PHLDB1 SGSM2	3.92e-05	192	109	7	7556_UP
Drug	Sulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; PC3; HT_HG-U133A	KMT2B SZT2 EML3 PHLDB1 MAST4 CDK13 SGSM2	4.05e-05	193	109	7	4322_UP
Drug	17-AAG; Down 200; 1uM; MCF7; HT_HG-U133A	SLC4A3 RASSF7 ARHGEF40 TESMIN MEGF8 FUT4 TNS1	4.19e-05	194	109	7	5914_DN
Drug	Piromidic acid [19562-30-2]; Up 200; 13.8uM; MCF7; HT_HG-U133A	WIPF1 SZT2 TESMIN MEGF8 AUTS2 GNAS EPN1	4.33e-05	195	109	7	3335_UP
Drug	Minocycline hydrochloride [13614-98-7]; Down 200; 8uM; PC3; HT_HG-U133A	WIPF1 CRTC1 EML3 SLC6A6 TLE1 GNAS FUT4	4.33e-05	195	109	7	5077_DN
Drug	Melatonin [73-31-4]; Up 200; 17.2uM; PC3; HT_HG-U133A	COL4A3 WAS CRTC1 PHLDB1 WIZ GLI2 SGSM2	4.33e-05	195	109	7	6293_UP
Drug	H-89, Dihydrochloride; Down 200; 0.5uM; PC3; HT_HG-U133A	WIPF1 NUCB1 MAST4 CDK13 GLI2 SGSM2 SETBP1	4.47e-05	196	109	7	6873_DN
Drug	Calycanthine [595-05-1]; Down 200; 11.6uM; MCF7; HT_HG-U133A	WAS NUCB1 EML3 SLC6A6 MAST4 SHARPIN FUT4	4.47e-05	196	109	7	2764_DN
Drug	Aceclofenac [89796-99-6]; Down 200; 11.2uM; PC3; HT_HG-U133A	TANK NUCB1 RASSF7 EML3 CCDC88C MAP1S GNAS	4.47e-05	196	109	7	7269_DN
Drug	0316684-0000 [391209-55-5]; Up 200; 10uM; MCF7; HT_HG-U133A	KREMEN2 CRTC1 RASSF7 MAST4 WIZ SHARPIN FUT4	4.62e-05	197	109	7	7052_UP
Drug	Nadide [53-84-9]; Up 200; 6uM; MCF7; HT_HG-U133A	HNF1B CYP2C9 SLC6A6 ARHGEF40 KMT2D TNS1 MN1	4.62e-05	197	109	7	6091_UP
Drug	Triamcinolone [124-94-7]; Up 200; 10.2uM; PC3; HT_HG-U133A	TANK WIPF1 DIDO1 CDK13 GLI2 SGSM2 FUT4	4.62e-05	197	109	7	5835_UP
Drug	thioridazine hydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A	SRCAP ADARB1 SLC4A3 ARHGEF40 MEGF8 TLE1 TNS1	4.77e-05	198	109	7	5916_DN
Drug	Harmane hydrochloride [21655-84-5]; Down 200; 18.2uM; PC3; HT_HG-U133A	HNF1B ADARB1 ARHGEF40 MEGF8 GLI2 FUT4 TNS1	4.77e-05	198	109	7	4584_DN
Drug	Dilazep dihydrochloride [20153-98-4]; Up 200; 6uM; PC3; HT_HG-U133A	CUX2 CYP2C9 TSPOAP1 CRTC1 CSF2RB TESMIN AUTS2	4.77e-05	198	109	7	3665_UP
Drug	Midodrine hydrochloride [3092-17-9]; Up 200; 13.8uM; HL60; HG-U133A	HNF1B WIPF1 NUCB1 SRCAP RASSF7 CDK13 SEZ6L	4.92e-05	199	109	7	1403_UP
Drug	Clomipramine hydrochloride [17321-77-6]; Up 200; 11.4uM; MCF7; HT_HG-U133A	CDIP1 WAS WIPF1 HCN4 DUSP4 SLC6A6 CDK13	5.08e-05	200	109	7	3182_UP
Drug	picoxystrobin	CYP2C19 CYP2C9	6.79e-05	3	109	2	ctd:C556557
Drug	mono-N-demethyladinazolam	CYP2C19 CYP2C9	6.79e-05	3	109	2	ctd:C050132
Drug	2-hydroxychlorpropamide	CYP2C19 CYP2C9	6.79e-05	3	109	2	CID003082454
Drug	Delavirdine	CYP2C19 CYP2C9	6.79e-05	3	109	2	ctd:D020008
Drug	AC1NS2PV	ERVK-6 CYP2C19 CYP2C9	1.15e-04	20	109	3	CID005352621
Drug	1-(6-((2-(dimethylamino)ethyl)(methyl)amino)-1,3-dimethyl-1H-pyrazolo(3,4-b)pyridine-5-carbonyl)-3-(3-isopropoxyphenyl)urea	CYP2C19 CYP2C9	1.35e-04	4	109	2	ctd:C558737
Drug	methysticin	CYP2C19 CYP2C9	1.35e-04	4	109	2	ctd:C076881
Drug	rabeprazole-thioether	CYP2C19 CYP2C9	1.35e-04	4	109	2	ctd:C523099
Drug	7,8-dihydromethysticin	CYP2C19 CYP2C9	1.35e-04	4	109	2	ctd:C107882
Drug	perillyl alcohol	CYP2C19 CYP2C9 SETBP1 GNAS	1.51e-04	56	109	4	CID000010819
Drug	bufuralol	CYP2C19 CYP2C9	2.25e-04	5	109	2	ctd:C010831
Drug	2-oxo-clopidogrel	CYP2C19 CYP2C9	2.25e-04	5	109	2	ctd:C540904
Drug	benfuracarb	CYP2C19 CYP2C9	2.25e-04	5	109	2	ctd:C096128
Drug	mono(2-ethyl-5-hydroxyhexyl) phthalate	CYP2C19 CYP2C9	2.25e-04	5	109	2	ctd:C479069
Drug	Spurr resin	COL4A3 CYP2C19 CYP2C9 FUT4	2.53e-04	64	109	4	CID006449895
Drug	Ethacrynic acid [58-54-8]; Up 200; 13.2uM; HL60; HG-U133A	TANK NUCB1 DIDO1 CRTC1 NECAP2 PIAS3	2.85e-04	187	109	6	1565_UP
Drug	Fenoprofen calcium salt dihydrate [53746-45-5]; Up 200; 7.2uM; PC3; HT_HG-U133A	SZT2 NUCB1 ARID5A WIZ MEGF8 CDK13	3.10e-04	190	109	6	4274_UP
Drug	0317956-0000 [391210-11-0]; Down 200; 10uM; MCF7; HT_HG-U133A	SZT2 KREMEN2 DUSP4 SLC6A6 WIZ CDK13	3.10e-04	190	109	6	3966_DN
Drug	4-ethylsulfonylnaphthalene-1-sulfonamide	HCN4 CHRD GNAS BSN TNS1	3.16e-04	123	109	5	CID000013296
Drug	C75; Down 200; 10uM; PC3; HT_HG-U133A	CDIP1 SRCAP SLC4A3 WIZ EPN1 TNS1	3.19e-04	191	109	6	6399_DN
Drug	Norcyclobenzaprine [303-50-4]; Up 200; 15.4uM; PC3; HT_HG-U133A	EML3 ARID5A MAST4 GLI2 TLE4 TCF7L1	3.19e-04	191	109	6	4190_UP
Drug	Quercetine dihydrate [6151-25-3]; Down 200; 11.8uM; HL60; HT_HG-U133A	SZT2 DIDO1 SRCAP RASSF7 ARHGEF40 FUT4	3.19e-04	191	109	6	2499_DN
Drug	5279552; Up 200; 22uM; MCF7; HT_HG-U133A_EA	ZNF219 WAS DUSP4 MAST4 TLE1 SGSM2	3.28e-04	192	109	6	960_UP
Drug	4,4'-cyclohexylidenebisphenol	CYP2C19 CYP2C9	3.36e-04	6	109	2	ctd:C570106
Drug	4',5-dihydroxydiclofenac	CYP2C19 CYP2C9	3.36e-04	6	109	2	CID003052567
Drug	avasimibe	CYP2C19 CYP2C9	3.36e-04	6	109	2	ctd:C423185
Drug	mono(2-ethyl-5-oxohexyl)phthalate	CYP2C19 CYP2C9	3.36e-04	6	109	2	ctd:C080276
Drug	AC1O5Z5L	CYP2C19 CYP2C9	3.36e-04	6	109	2	CID006443527
Drug	Cyclodextrins	CYP2C19 CYP2C9	3.36e-04	6	109	2	ctd:D003505
Drug	3'-hydroxydiclofenac	CYP2C19 CYP2C9	3.36e-04	6	109	2	CID000112230
Drug	4'-hydroxyflurbiprofen	CYP2C19 CYP2C9	3.36e-04	6	109	2	CID000157678
Drug	mepirodipine	CYP2C19 CYP2C9	3.36e-04	6	109	2	ctd:C050699
Drug	Lasalocid sodium salt [25999-20-6]; Up 200; 6.6uM; HL60; HT_HG-U133A	COL4A3 SLC6A6 CCDC88C KMT2D WIZ SEZ6L	3.37e-04	193	109	6	3021_UP
Drug	Gramine [87-52-5]; Up 200; 23uM; MCF7; HT_HG-U133A	WIPF1 SLC6A6 CSF2RB SETBP1 FUT4 TNS1	3.37e-04	193	109	6	4118_UP
Drug	PHA-00851261E [724719-49-7]; Down 200; 10uM; PC3; HT_HG-U133A	HNF1B SZT2 ADARB1 CDK13 SGSM2 TNS1	3.37e-04	193	109	6	3773_DN
Drug	Beta-sistosterol [83-46-5]; Down 200; 9.6uM; MCF7; HT_HG-U133A	WIPF1 CRTC1 SRCAP NECAP2 MAST4 TLE1	3.37e-04	193	109	6	4154_DN
Drug	6-Furfurylaminopurine [525-79-1]; Up 200; 18.6uM; PC3; HT_HG-U133A	SRCAP ADARB1 CDK13 FUT4 EPN1 TNS1	3.37e-04	193	109	6	4477_UP
Drug	Mexiletine hydrochloride [5370-01-4]; Down 200; 18.6uM; MCF7; HT_HG-U133A	WIPF1 CRTC1 SRCAP MAST4 WIZ SETBP1	3.37e-04	193	109	6	3973_DN
Drug	2-deoxy-D-glucose; Down 200; 10000uM; MCF7; HG-U133A	SZT2 KREMEN2 SRCAP WIZ CHRD TNS1	3.47e-04	194	109	6	344_DN
Drug	ICI 182,780; Down 200; 1uM; HL60; HT_HG-U133A	SRCAP EML3 MRTFB PIAS3 CDK13 SGSM2	3.47e-04	194	109	6	6165_DN
Drug	Dosulepin hydrochloride [897-15-4]; Down 200; 12uM; MCF7; HT_HG-U133A	KREMEN2 SRCAP RASSF7 MAST4 WIZ MAP1S	3.47e-04	194	109	6	2864_DN
Drug	Flurandrenolide [1524-88-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A	WIPF1 KREMEN2 SRCAP SLC6A6 PHLDB1 AUTS2	3.47e-04	194	109	6	6039_DN
Drug	2-propylpentanoic acid; Up 200; 200uM; PC3; HT_HG-U133A	KMT2B DIDO1 PHLDB1 GLI2 FUT4 TCF7L1	3.56e-04	195	109	6	1214_UP
Drug	Mepenzolate bromide [76-90-4]; Up 200; 9.6uM; MCF7; HT_HG-U133A	CDIP1 CYP2C9 CRTC1 CSF2RB TLE1 CHRD	3.56e-04	195	109	6	3829_UP
Drug	Fluspirilen [1841-19-6]; Up 200; 8.4uM; PC3; HT_HG-U133A	HNF1B CRTC1 ADARB1 CDK13 TLE1 ALPK3	3.56e-04	195	109	6	6662_UP
Drug	Pralidoxime chloride [51-15-0]; Down 200; 23.2uM; PC3; HT_HG-U133A	HNF1B EML3 CCDC88C MAST4 TNS1 MN1	3.56e-04	195	109	6	6283_DN
Drug	Metampicillin sodium salt [6489-61-8]; Up 200; 10.4uM; PC3; HT_HG-U133A	COL4A3 HNF1B WAS SZT2 SRCAP ARID5A	3.56e-04	195	109	6	5115_UP
Drug	Benzathine benzylpenicillin [5928-84-7]; Up 200; 4.2uM; MCF7; HT_HG-U133A	SRCAP PPP1R13L CDK13 TLE1 AUTS2 GNAS	3.56e-04	195	109	6	7359_UP
Drug	Betulinic acid [472-15-1]; Down 200; 8.8uM; MCF7; HT_HG-U133A	HNF1B WIPF1 SZT2 MAST4 WIZ SETBP1	3.56e-04	195	109	6	4181_DN
Drug	Meropenem [96036-03-2]; Up 200; 10.4uM; MCF7; HT_HG-U133A	CUX2 CYP2C19 WIPF1 EML3 SLC6A6 EPN1	3.66e-04	196	109	6	3564_UP
Drug	Cefsulodin sodium salt [52152-93-9]; Down 200; 7.2uM; MCF7; HT_HG-U133A	CYP2C9 SZT2 KREMEN2 EML3 CDK13 SHARPIN	3.66e-04	196	109	6	4148_DN
Drug	DO 897/99; Up 200; 8.2uM; HL60; HG-U133A	CYP2C9 KMT2B NUCB1 TLE1 GNAS SEZ6L	3.66e-04	196	109	6	1728_UP
Drug	Apomorphine hydrochloride hemihydrate [41372-20-7]; Up 200; 6.4uM; MCF7; HT_HG-U133A	WIPF1 DUSP4 NUCB1 EML3 AUTS2 FUT4	3.66e-04	196	109	6	1505_UP
Drug	Lactobionic acid [96-82-2]; Down 200; 11.2uM; PC3; HT_HG-U133A	KMT2B WIPF1 CRTC1 SLC4A3 WIZ SGSM2	3.66e-04	196	109	6	6605_DN
Drug	Etofenamate [30544-47-9]; Down 200; 10.8uM; HL60; HT_HG-U133A	RASSF7 EML3 ARHGEF40 CSF2RB MAP1S SGSM2	3.66e-04	196	109	6	2907_DN
Drug	Epivincamine [6835-99-0]; Down 200; 11.2uM; PC3; HT_HG-U133A	HNF1B CRTC1 NECAP2 WIZ TLE1 TNS1	3.66e-04	196	109	6	4500_DN
Drug	S(+)-Terguride [37686-84-3]; Down 200; 11.8uM; PC3; HT_HG-U133A	HNF1B NECAP2 TLE1 SGSM2 TNS1 MN1	3.66e-04	196	109	6	6299_DN
Drug	Josamycin [16846-24-5]; Up 200; 4.8uM; MCF7; HT_HG-U133A	CDIP1 CRTC1 SRCAP CDK13 AUTS2 SEZ6L	3.66e-04	196	109	6	5692_UP
Drug	Protoveratrine A [143-57-7]; Up 200; 5uM; MCF7; HT_HG-U133A	COL4A3 HNF1B WAS SRCAP PHLDB1 MEGF8	3.66e-04	196	109	6	2800_UP
Drug	Chlorogenic acid [327-97-9]; Up 200; 11.2uM; PC3; HT_HG-U133A	TANK CRTC1 ADARB1 WIZ TLE1 TNS1	3.76e-04	197	109	6	4024_UP
Drug	Benzamil hydrochloride [2898-76-2]; Up 200; 11.2uM; MCF7; HT_HG-U133A	CDIP1 KREMEN2 DUSP4 CRTC1 SRCAP MAP1S	3.76e-04	197	109	6	4760_UP
Drug	Tiletamine hydrochloride; Up 200; 15.4uM; MCF7; HT_HG-U133A	WIPF1 SLC6A6 WIZ MEGF8 TLE1 GNAS	3.76e-04	197	109	6	6516_UP
Drug	(+) -Levobunolol hydrochloride [47141-41-3]; Down 200; 12.2uM; MCF7; HT_HG-U133A	WIPF1 KREMEN2 SRCAP EML3 TLE1 FUT4	3.76e-04	197	109	6	3355_DN
Drug	Levocabastine hydrochloride [79547-78-7]; Down 200; 8.8uM; PC3; HT_HG-U133A	TANK RASSF7 CCDC88C NECAP2 CDK13 SGSM2	3.76e-04	197	109	6	7249_DN
Drug	N6-methyladenosine [1867-73-8]; Down 200; 14.2uM; PC3; HT_HG-U133A	WAS PHLDB1 MAST4 TLE1 TNS1 MN1	3.76e-04	197	109	6	6732_DN
Drug	Diloxanide furoate [3736-81-0]; Down 200; 12.2uM; MCF7; HT_HG-U133A	CRTC1 SRCAP SLC6A6 TESMIN CDK13 AUTS2	3.76e-04	197	109	6	3399_DN
Drug	Cefotaxime sodium salt [64485-93-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A	KREMEN2 EML3 MAST4 MAP1S CDK13 TLE4	3.76e-04	197	109	6	7186_DN
Drug	CGX 0596987; Up 200; 20uM; MCF7; HT_HG-U133A	COL4A3 HCN4 PHLDB1 MEGF8 CDK13 TNS1	3.76e-04	197	109	6	6412_UP
Drug	Ofloxacin [82419-36-1]; Up 200; 11uM; PC3; HT_HG-U133A	ZNF219 WIPF1 TSPOAP1 CRTC1 ARHGEF40 PTPRO	3.86e-04	198	109	6	3673_UP
Drug	Nicardipine hydrochloride [54527-84-3]; Up 200; 7.8uM; MCF7; HT_HG-U133A	ARHGEF40 WIZ TESMIN MEGF8 CDK13 TNS1	3.86e-04	198	109	6	3215_UP
Drug	Oxaprozin [21256-18-8]; Up 200; 13.6uM; PC3; HT_HG-U133A	COL4A3 ZNF219 SRCAP ADARB1 CDK13 TLE1	3.86e-04	198	109	6	4530_UP
Drug	Myosmine [532-12-7]; Down 200; 27.4uM; PC3; HT_HG-U133A	ZNF219 NUCB1 CRTC1 SRCAP NECAP2 MAST4	3.86e-04	198	109	6	4293_DN
Drug	Paromomycin sulfate [1263-89-4]; Down 200; 5.6uM; PC3; HT_HG-U133A	KMT2B WIPF1 ADARB1 EML3 MEGF8 SGSM2	3.86e-04	198	109	6	4595_DN
Drug	Cefadroxil [50370-12-2]; Down 200; 11uM; MCF7; HT_HG-U133A	WIPF1 KREMEN2 DUSP4 CDK13 AUTS2 FUT4	3.86e-04	198	109	6	3259_DN
Drug	Oxamniquine [21738-42-1]; Down 200; 14.4uM; MCF7; HT_HG-U133A	TANK SZT2 KREMEN2 SLC6A6 CCDC88C CDK13	3.86e-04	198	109	6	7344_DN
Disease	Wiskott-Aldrich Syndrome	WAS WIPF1	1.40e-05	2	111	2	C0043194
Disease	autosomal recessive nonsyndromic deafness 36 (implicated_via_orthology)	ESPN ESPNL	1.40e-05	2	111	2	DOID:0110494 (implicated_via_orthology)
Disease	X-21258 measurement	CYP2C19 CYP2C9	4.20e-05	3	111	2	EFO_0800802
Disease	event-related brain oscillation	ARID5A GNAS	8.37e-05	4	111	2	EFO_0004358
Disease	resting heart rate	COL4A3 WIPF1 HCN4 ARHGEF40 MN1	2.56e-04	149	111	5	EFO_0004351
Disease	JT interval	SLC4A3 PRR35 CDK13 ARID2 ALPK3 TCF7L1	3.60e-04	248	111	6	EFO_0007885
Disease	restless legs syndrome (implicated_via_orthology)	MEIS3 MEIS3P2	3.87e-04	8	111	2	DOID:0050425 (implicated_via_orthology)
Disease	Arhinencephaly	TGIF1 GLI2	3.87e-04	8	111	2	C0078982
Disease	body fat percentage	CRTC1 PARD3B POM121C ADARB1 EML3 SETBP1 AUTS2 IGSF9B	5.28e-04	488	111	8	EFO_0007800
Disease	mean arterial pressure	CUX2 CYP2C19 SZT2 DUSP4 POM121C AUTS2 GNAS TNS1	6.10e-04	499	111	8	EFO_0006340
Disease	Holoprosencephaly sequence	TGIF1 GLI2	6.19e-04	10	111	2	cv:C0079541
Disease	neuroimaging measurement	KMT2B SZT2 COL22A1 POM121C SH2D5 CCDC88C ZNF106 ZBTB32 MAST4 TLE4 TNS1 INO80E	7.03e-04	1069	111	12	EFO_0004346
Disease	Semantic-Pragmatic Disorder	SHANK3 SETBP1	7.54e-04	11	111	2	C0454655
Disease	X-11308 measurement	CYP2C19 CYP2C9	7.54e-04	11	111	2	EFO_0800693
Disease	Auditory Processing Disorder, Central	SHANK3 SETBP1	7.54e-04	11	111	2	C0751257
Disease	Language Delay	SHANK3 SETBP1	7.54e-04	11	111	2	C0023012
Disease	Language Development Disorders	SHANK3 SETBP1	7.54e-04	11	111	2	C0023014
Disease	Speech Delay	SHANK3 SETBP1	7.54e-04	11	111	2	C0241210
Disease	pulmonary function measurement, forced expiratory volume, smoking behaviour measurement	INTS12 TNS1	9.03e-04	12	111	2	EFO_0003892, EFO_0004314, EFO_0005671
Disease	thymol sulfate measurement	CYP2C19 CYP2C9	9.03e-04	12	111	2	EFO_0021170
Disease	intracranial aneurysm (is_implicated_in)	COL22A1 KMT2D	9.03e-04	12	111	2	DOID:10941 (is_implicated_in)
Disease	household income	TANK MAST4 SGSM2 TLE4 CTNND1 BSN	1.04e-03	304	111	6	EFO_0009695
Disease	hematologic cancer (implicated_via_orthology)	CUX2 PIAS3	1.06e-03	13	111	2	DOID:2531 (implicated_via_orthology)
Disease	dystonia (is_implicated_in)	KMT2B TSPOAP1	1.24e-03	14	111	2	DOID:543 (is_implicated_in)
Disease	Alobar Holoprosencephaly	TGIF1 GLI2	1.43e-03	15	111	2	C0431363
Disease	Lobar Holoprosencephaly	TGIF1 GLI2	1.63e-03	16	111	2	C0431362
Disease	Semilobar Holoprosencephaly	TGIF1 GLI2	1.63e-03	16	111	2	C0751617
Disease	oral squamous cell carcinoma (is_marker_for)	KMT2D ARID2 CTNND1	1.75e-03	63	111	3	DOID:0050866 (is_marker_for)
Disease	coronary artery disease	AMBN CUX2 HCN4 DOK7 MAGI3 GGT7 MAST4 MAP1S PTPRO BSN TNS1 SEZ6L	1.80e-03	1194	111	12	EFO_0001645
Disease	Holoprosencephaly	TGIF1 GLI2	1.84e-03	17	111	2	C0079541
Disease	multiple sclerosis	ESPN TAGAP TSPOAP1 PLEKHG5 ETV3L PHLDB1 CSF2RB SGSM2	1.85e-03	594	111	8	MONDO_0005301
Disease	level of Phosphatidylcholine (20:4_0:0) in blood serum	DOK7 TCF7L1	2.06e-03	18	111	2	OBA_2045110
Disease	diabetes mellitus	HNF1B CRTC1 TLE1	2.17e-03	68	111	3	EFO_0000400
Disease	leukemia (implicated_via_orthology)	MEIS3 MEIS3P2	2.30e-03	19	111	2	DOID:1240 (implicated_via_orthology)
Disease	aspartate aminotransferase measurement, serum alanine aminotransferase measurement, low density lipoprotein triglyceride measurement, body fat percentage, high density lipoprotein cholesterol measurement, sex hormone-binding globulin measurement	PARD3B POM121C ADARB1 EML3 SETBP1 AUTS2	2.59e-03	364	111	6	EFO_0004612, EFO_0004696, EFO_0004735, EFO_0004736, EFO_0007800, EFO_0009946
Disease	parental longevity	CUX2 ZBTB22 MAGI3 COL22A1 POM121C SETBP1 BSN	2.69e-03	494	111	7	EFO_0007796
Disease	cortical thickness	KMT2B ESPNL ETV3L ZNF106 PHLDB1 ARHGEF40 ZBTB32 MAST4 SHARPIN AUTS2 TNS1	3.19e-03	1113	111	11	EFO_0004840

Protein segments in the cluster

Peptide	Gene	Start	Entry
APLLPPRGISRPSSG	nan	86	Q6ZRM9
GSPELLPRSPKPSGL	GNAS	131	P84996
PGLPGRAAVTKPLPS	SLC4A3	176	P48751
LPPTFPSSPGLGSKR	ARID5A	431	Q03989
PLLEEKSGAPPTPGR	CDIP1	16	Q9H305
GLPSPPLPEEALGTR	ARHGEF40	211	Q8TER5
DPRPALGTPSPKLSV	CSMD3	3476	Q7Z407
LKIISLPGSPGPPGT	COL4A3	1351	Q01955
LPKDDIPGLPRSPSG	AMBN	356	Q9NP70
RGPRKSLVPGSPGTP	ALPK3	1396	Q96L96
PKRGPSTPGGKLILP	ARID2	1066	Q68CP9
DPAALLPGASPKSPG	RCSD1	96	Q6JBY9
LPKVAPGPLLPGGST	CUX2	1341	O14529
LPPELPGGDDLSKSP	CDK13	651	Q14004
PGKGESGPSALLTPP	FBXL19	6	Q6PCT2
KTLTPEPAPSLSRPG	RASSF7	126	Q02833
LPGSSSPLLAQPRKP	ARHGAP39	281	Q9C0H5
RGSGPKDLDLPPGSP	TSPOAP1	561	O95153
LSLSPSPEGLGEPPA	TSPOAP1	776	O95153
TLPPELVPPSFRGGK	ITSN2	321	Q9NZM3
KPPPPLTLGKTGLSR	INTS12	361	Q96CB8
PRLGGKPSSPSLSPL	PARD3B	356	Q8TEW8
LPKPRSGLASGEPRP	ESPNL	691	Q6ZVH7
GITPLPLSRGPVPAK	MAP1S	366	Q66K74
PPSIIRSGSPKLDPS	MAGI3	691	Q5TCQ9
LGGPRPIRSLPPLSS	GPR179	26	Q6PRD1
DPPSGLAPPLSRKQG	FUT4	341	P22083
PELGLPRGTIGKPTP	ESPN	416	B1AK53
PGPGSTSRRLDPKEP	BSN	71	Q9UPA5
GLPAKSPGRSPDLAP	CCDC88C	1976	Q9P219
TFLPSGRPPLPGSLL	GGT7	291	Q9UJ14
LRSLRKGPGLLSPPS	FAM214B	321	Q7L5A3
STPVRKPGPLPSSLD	MRTFB	376	Q9ULH7
GLKPEFLSRPPGPSL	AUTS2	681	Q8WXX7
GPLLASLSGSTRPPP	MEGF8	96	Q7Z7M0
SPGTPRLGRKTSPGP	KANK1	1331	Q14678
PQPLPPGLDSDGLKR	MEIS3	41	Q99687
PPPSGPLRLGTAALL	KREMEN2	291	Q8NCW0
PHTRNTKLPPLPGSG	GLI2	751	P10070
GVRVLSLGPAPEPPK	KMT2B	2171	Q9UMN6
MPPSGPRGTLLLLPL	NUCB1	1	Q02818
GSLQPRPPGLLSDPS	ADARB1	481	P78563
TLPRKTSSGSLPPPL	HCN4	1151	Q9Y3Q4
KRSPPLGGAPSPSSL	INO80E	96	Q8NBZ0
PQPLPPGLDSDGLKR	MEIS3P2	41	A8K0S8
LRKGPLIGPPSDPVT	PTPRO	511	Q16827
DSKPPTTLLGLIPAP	POM121C	631	A8CG34
RSPSGTPAPGLLKVP	PRR35	291	P0CG20
LGSASRAPGKSPPEP	FAM171A2	21	A8MVW0
GPPSLSLSPKPTVGR	NLGN3	6	Q9NZ94
VGPSESKPRGTSPLP	ERVK-21	171	P62683
VGPSESKPRGTSPLP	ERVK-24	171	P63145
VGPSESKPRGTSPLP	ERVK-6	171	Q7LDI9
VGPSESKPRGTSPLP	ERVK-8	171	P62685
VGPSESKPRGTSPLP	ERVK-9	171	P63126
PGLGPGPLSLRSKPS	CSF2RB	826	P32927
GPLSLRSKPSSPGPG	CSF2RB	831	P32927
RQSSGRGKLPPGPTP	CYP2C19	21	P33261
RLPPGGPLLPSASLT	CRTC1	391	Q6UUV9
GPLLPSASLTRGPQP	CRTC1	396	Q6UUV9
LLSQLKGPRGGPPPS	DIDO1	1896	Q9BTC0
PPGKPGLSSLLSPGD	COL22A1	1091	Q8NFW1
PLDAKPQPTSGGRPL	MAST4	2281	O15021
SLVSRPGPTPPGAKA	EPN1	486	Q9Y6I3
SGIRSLEELPSGPPP	EML3	231	Q32P44
RQSSGRGKLPPGPTP	CYP2C9	21	P11712
TKGPFGLRPVLPDPS	DOK7	206	Q18PE1
PAKSPGSPLLLRGLS	C1orf127	386	Q8N9H9
QPPLPLGDPGRASKA	GJA3	406	Q9Y6H8
KPDILLPGPRSLPGA	ETV3L	266	Q6ZN32
PSGPLRERGKTPATP	DUSP4	346	Q13115
PLSPKGRPSSPRTPL	PPP1R13L	111	Q8WUF5
RPLGSSTQGLRPPLP	CCDC24	236	Q8N4L8
SLASLDSLRKGGPPP	CTNND1	346	O60716
PGRLLPSAPTLRSPG	KIFC2	771	Q96AC6
GPGLPPSLPELRTKT	NEURL4	991	Q96JN8
PLVTGSPKLPPRGVG	MN1	1076	Q10571
PSGSTLPGPPKITLA	TESMIN	291	Q9Y4I5
LPLSPGSGAEPDTKP	HNF1B	46	P35680
KVGESSSRPAPGPLP	GAREM2	561	Q75VX8
GPRLSPLGPSKAFEP	GAREM2	731	Q75VX8
SSLRSDDGLGPPLPP	SZT2	1656	Q5T011
LLSSSTEKPGPPGDP	SEZ6L	156	Q9BYH1
DILKPSPGKSPGTRP	SLC6A6	16	P31641
APSSPLPGVPKSRLE	TMC3	801	Q7Z5M5
SKEPLPGHGLSPLPE	TAGAP	651	Q8N103
PGGPLTEALPPARKE	NDUFB9	146	Q9Y6M9
PGPTGEVPLKPLSSS	SH2D5	161	Q6ZV89
IPPDRPPGASAGLTK	SGSM2	526	O43147
RPPNLRGSSLPGKPT	SMIM14	71	Q96QK8
STLKGPPPEADLPRS	SHARPIN	151	Q9H0F6
PFPSLDSPGKAIRGP	TANK	351	Q92844
PRPGLLSLAKPLDAP	WIZ	946	O95785
LPLSPLAGRPGKPGA	WIZ	1311	O95785
LPSPLGVLSGTSRPP	SRCAP	1086	Q6ZRS2
PTLTPGRLPTPTLGT	SRCAP	1346	Q6ZRS2
VGPSESKPRGTSPLP	ERVK-9	171	P63128
RTPLRPGPSSALGPL	LINC00612	41	Q8N6U2
LLGPPGTPGPRRLLK	CHRD	586	Q9H2X0
IPPTLLAPGTLLGPK	PIAS3	96	Q9Y6X2
LGRPLSPKPSSPGSV	TGIF1	281	Q15583
GLRGLLRPSPPFSKP	PPOX	111	P50336
SLSLPILRPAGTGPP	PLEKHG5	166	O94827
TSATPGLRPGLGKPP	TLE1	331	Q04724
LSRLLPEPGPSDSPG	TMC8	646	Q8IU68
PLTGKPLDPSSPLAL	SHANK3	1096	Q9BYB0
GSQPPLLSRPLPLGS	TCF7L1	536	Q9HCS4
GLSRSLPPPPPAKGS	PKMYT1	46	Q99640
VPGKPPGVDPLASSL	TLE4	346	Q04727
QPKAGLPRGLPPTSL	IGSF9B	1071	Q9UPX0
LSPPPGLPSKIGSIS	KIF21A	1211	Q7Z4S6
ALPSPPTPSDGGTKR	PLCD3	31	Q8N3E9
GGLSLSPSPERRKPP	SCARF2	646	Q96GP6
PSGVRSPPGLAKTPL	TNS1	966	Q9HBL0
SPPGLAKTPLSALGL	TNS1	971	Q9HBL0
KGRSGPLPPVPLGIA	WAS	336	P42768
PPLGPSSSLLSLPGL	TBC1D10B	651	Q4KMP7
PPLLPPGGRSTSAKP	WIPF1	126	O43516
RPPSPGLRGLLTDSP	PHLDB1	321	Q86UU1
GSEESLRKLPGPLPP	ZBTB32	221	Q9Y2Y4
EPLLSTPGPGKGIPV	SETBP1	36	Q9Y6X0
PSGPLLPELSKLGFP	ZNF106	711	Q9H2Y7
PTGPSLPSKRESPGV	ZBTB22	581	O15209
SKLGPLRAPGPASGP	ZNF219	326	Q9P2Y4
PSLGLPAASAGPKRP	nan	116	Q6ZQT7
LPPSKLSGPILGPGS	KMT2D	2751	O14686
SLLPPPPGGKTSTLI	NECAP2	186	Q9NVZ3